Skip to Content

Fidaxomicin Dosage

Medically reviewed by Drugs.com. Last updated on Jan 15, 2021.

Applies to the following strengths: 200 mg; 40 mg/mL

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Clostridial Infection

200 mg orally twice a day for 10 days

Use: For the treatment of Clostridioides difficile-associated diarrhea (CDAD)

Usual Pediatric Dose for Clostridial Infection

6 Months to Less Than 18 Years:
Oral suspension:
-Weight 4 to less than 7 kg: 80 mg orally twice a day
-Weight 7 to less than 9 kg: 120 mg orally twice a day
-Weight 9 to less than 12.5 kg: 160 mg orally twice a day
-Weight at least 12.5 kg: 200 mg orally twice a day

Tablets:
-Weight at least 12.5 kg: 200 mg orally twice a day

Duration of therapy: 10 days

Use: For the treatment of CDAD

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:
Known hypersensitivity to the active component or any of the ingredients

Safety and efficacy have not been established in patients younger than 6 months.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Administer with or without food.
-Administer tablets to pediatric patients weighing at least 12.5 kg and able to swallow tablets; if unable to swallow tablets, may administer the oral suspension
-Remove the oral suspension from the refrigerator 15 minutes before each administration.
-Shake the oral suspension vigorously until consistency is even.
-Use an oral dosing syringe to administer the oral suspension.

Storage requirements:
-Granules for oral suspension: Store in original package at 20C to 25C (68F to 77F); excursions permitted to 15C to 30C (59F to 86F); do not open pouch until time of use.
-Reconstituted oral suspension: Store capped in original bottle in refrigerator at 2C to 8C (36F to 46F) for up to 12 days; discard after 12 days.
-Tablets: Store in original bottle at 20C to 25C (68F to 77F); excursions permitted to 15C to 30C (59F to 86F).

Reconstitution/preparation techniques:
-Oral suspension: The manufacturer product information should be consulted.

General:
-To reduce the development of drug-resistant organisms and maintain effective therapy, this drug should be used only to treat infections proven or strongly suspected to be caused by C difficile.
-Culture and susceptibility information should be considered when selecting/modifying antibacterial therapy or, if no data are available, local epidemiology and susceptibility patterns may be considered when selecting empiric therapy.

Patient advice:
-Read the US FDA-approved patient labeling (Patient Information).
-Avoid missing doses and complete the entire course of therapy.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.